SAB Biotherapeutics, Inc.
SABS· Nasdaq
Released Aug 9, 2022, after the close
10-Q filed Aug 10, 2022, 41 days after period end · 0000950170-22-016221
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2022 | Q2 2021 |
|---|---|---|
| Revenue | $6.35M | $18.21M |
| Net Income | -$4.78M | -$2.94M |
| EPS Diluted | -$0.11 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SAB Biotherapeutics, Inc. · CIK 1833214 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 10, 2022 · 41 d after period end
2.6% from the close of Aug 9, 2022 to the close of Aug 10, 2022, the first after the release.